Table 2.
Treatment rate ratios for chemotherapy alone (CT), radiotherapy alone (RT) and chemotherapy & radiotherapy (CTRT) within 6 months of diagnosis of lung, oesophageal, pancreatic and stomach cancers in 2013–2014 from three unadjusted and three fully adjusted multivariable models with cancer site, sex, age at diagnosis, deprivation, ethnicity and Charlson comorbidity index
| RT | CT | CTRT | |||||||
|---|---|---|---|---|---|---|---|---|---|
| %a | TRR (95% CI) | %a | TRR (95% CI) | %a | TRR (95% CI) | ||||
| Unadjusted | Fully adjusted | Unadjusted | Fully adjusted | Unadjusted | Fully adjusted | ||||
| Sex | |||||||||
| Male | 13 | Ref | Ref | 24 | Ref | Ref | 11 | Ref | Ref |
| Female | 12 | 0.88 (0.84, 0.92) | 0.85 (0.81, 0.89) | 23 | 0.90 (0.86, 0.93) | 0.97 (0.93, 1.00) | 12 | 1.02 (0.97, 1.08) | 0.95 (0.91, 1.01) |
| p for heterogeneityb | <0.0001 | <0.0001 | <0.0001 | 0.08 | 0.36 | 0.08 | |||
| Age at cancer diagnosis | |||||||||
| <50 | 9 | 0.57 (0.48, 0.67) | 0.65 (0.55, 0.77) | 45 | 1.35 (1.25, 1.46) | 1.24 (1.15, 1.34) | 21 | 1.11 (0.99, 1.24) | 1.41 (1.26, 1.58) |
| 50–59 | 12 | 0.86 (0.79, 0.94) | 0.91 (0.83, 0.99) | 34 | 1.04 (0.99, 1.10) | 1.01 (0.95, 1.06) | 22 | 1.27 (1.18, 1.36) | 1.33 (1.24, 1.43) |
| 60–69 | 13 | Ref | Ref | 32 | Ref | Ref | 17 | Ref | Ref |
| 70–79 | 14 | 1.21 (1.14, 1.29) | 1.20 (1.13, 1.28) | 24 | 0.78 (0.75, 0.82) | 0.79 (0.76, 0.83) | 9 | 0.55 (0.51, 0.58) | 0.56 (0.53, 0.60) |
| 80+ | 12 | 1.22 (1.14, 1.30) | 1.13 (1.05, 1.21) | 7 | 0.21 (0.20, 0.23) | 0.22 (0.21, 0.24) | 2 | 0.14 (0.12, 0.15) | 0.15 (0.13, 0.17) |
| p for heterogeneityb | <0.0001 | <0.0001 | <0.0001 | <0.0001 | <0.0001 | <0.0001 | |||
| Charlson comorbidity index | |||||||||
| 0 | 13 | Ref | Ref | 26 | Ref | Ref | 13 | Ref | Ref |
| 1 | 12 | 1.01 (0.93, 1.09) | 0.95 (0.88, 1.03) | 19 | 0.76 (0.71, 0.81) | 0.86 (0.81, 0.91) | 9 | 0.70 (0.63, 0.76) | 0.81 (0.74, 0.89) |
| 2 | 12 | 1.08 (0.98, 1.20) | 0.99 (0.89, 1.09) | 16 | 0.63 (0.58, 0.69) | 0.74 (0.68, 0.81) | 8 | 0.64 (0.56, 0.73) | 0.78 (0.69, 0.89) |
| 3+ | 12 | 1.15 (1.03, 1.28) | 0.98 (0.88, 1.10) | 11 | 0.43 (0.39, 0.48) | 0.57 (0.51, 0.64) | 4 | 0.32 (0.26, 0.38) | 0.41 (0.34, 0.50) |
| p for heterogeneityb | 0.04 | 0.67 | <0.0001 | <0.0001 | <0.0001 | <0.0001 | |||
| Deprivation quintile | |||||||||
| 1: least deprived | 12 | Ref | Ref | 27 | Ref | Ref | 12 | Ref | Ref |
| 2 | 12 | 1.04 (0.96, 1.13) | 1.02 (0.94, 1.11) | 25 | 0.95 (0.90, 1.01) | 0.95 (0.90, 1.01) | 12 | 1.04 (0.95, 1.14) | 0.96 (0.88, 1.04) |
| 3 | 13 | 1.12 (1.03, 1.22) | 1.09 (1.00, 1.18) | 23 | 0.88 (0.83, 0.93) | 0.89 (0.84, 0.94) | 11 | 1.01 (0.93, 1.10) | 0.90 (0.82, 0.98) |
| 4 | 13 | 1.09 (1.00, 1.18) | 1.04 (0.96, 1.13) | 23 | 0.86 (0.81, 0.92) | 0.86 (0.81, 0.91) | 11 | 1.04 (0.96, 1.14) | 0.84 (0.77, 0.91) |
| 5: most deprived | 13 | 1.14 (1.05, 1.23) | 1.08 (1.00, 1.18) | 22 | 0.85 (0.80, 0.90) | 0.82 (0.78, 0.87) | 11 | 1.07 (0.98, 1.17) | 0.78 (0.71, 0.85) |
| p for heterogeneityb | 0.01 | 0.18 | <0.0001 | <0.0001 | 0.48 | <0.0001 | |||
| Ethnicity | |||||||||
| White | 13 | Ref | Ref | 24 | Ref | Ref | 11 | Ref | Ref |
| Non-white | 12 | 0.85 (0.75, 0.96) | 0.91 (0.80, 1.04) | 29 | 1.13 (1.04, 1.22) | 1.01 (0.92, 1.10) | 14 | 1.07 (0.95, 1.21) | 1.07 (0.95, 1.21) |
| Unknown | 11 | 0.93 (0.81, 1.08) | 0.93 (0.81, 1.07) | 17 | 0.80 (0.71, 0.89) | 0.75 (0.67, 0.84) | 7 | 0.67 (0.56, 0.79) | 0.67 (0.56, 0.79) |
| p for heterogeneityb | 0.03 | 0.24 | <0.0001 | <0.0001 | <0.0001 | <0.0001 | |||
| Cancer site | |||||||||
| NSCLC | 18 | Ref | Ref | 18 | Ref | Ref | 12 | Ref | Ref |
| SCLC | 5 | 0.25 (0.22, 0.29) | 0.26 (0.23, 0.29) | 33 | 1.89 (1.79, 1.99) | 1.61 (1.52, 1.70) | 32 | 3.31 (3.12, 3.51) | 2.91 (2.74, 3.09) |
| Oesophagus | 10 | 0.47 (0.43, 0.52) | 0.47 (0.42, 0.52) | 37 | 2.04 (1.92, 2.16) | 1.88 (1.77, 1.99) | 8 | 0.57 (0.51, 0.64) | 0.47 (0.42, 0.53) |
| Stomach | 5 | 0.25 (0.21, 0.29) | 0.25 (0.21, 0.29) | 36 | 2.14 (2.02, 2.28) | 2.16 (2.03, 2.30) | 4 | 0.26 (0.21, 0.31) | 0.23 (0.19, 0.27) |
| Pancreas | 1 | 0.08 (0.07, 0.10) | 0.09 (0.07, 0.10) | 27 | 1.86 (1.76, 1.96) | 1.78 (1.68, 1.87) | 1 | 0.12 (0.10, 0.15) | 0.10 (0.09, 0.13) |
| p for heterogeneityb | <0.0001 | <0.0001 | <0.0001 | <0.0001 | <0.0001 | <0.0001 | |||
CI confidence interval, NSCLC non-small cell lung cancer, SCLC small cell lung cancer, TRR treatment rate ratio.
a Proportion of patients recorded to receive treatment in each category.
b Performed jointly across all categories of each variable, using a post-estimation Wald test